Beam Therapeutics Inc (BEAM)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 29% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- QualityRevenue growing 159% y/y-2
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is regulatory, stemming from the patent dispute ruling. There is a moderate probability the move continues as the legal overhang is resolved, but analyst reiterations provide support. Informational only — not financial advice.
- Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are InvestableSeekingAlpha · 2026-07-09
- Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics CaseBenzinga · 2026-07-08
- B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price TargetBenzinga · 2026-07-08
- HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price TargetBenzinga · 2026-07-07
- Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In BiotechSeekingAlpha · 2026-06-30
Any AI summary is an interpretation of public news, not advice or a price target.